23andMe Holding Co.

Good morning, and welcome to 23andMe's fiscal year 2022 third quarter financial results conference call. As a reminder, this call is being recorded. At this time, all participants are on a listen-only mode. After prepared remarks, there will be a question and answer session. I will now turn the call over to Wade Walk, Vice President of Investor Relations, to lead the call off. Thank you. Please go ahead.

Thank you. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued earlier today reporting our financial results for the quarter. A replay of today's webcast will also be available on our website for a limited time within 24 hours after the event. Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods, are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in our press release. which applies to this call. Also, please refer to our SEC filings, which can be found on our website and the SEC's website, for a discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliation to U.S. GAAP may be found in our earnings release. Joining us on our call today are Ann Wojcicki, our chief executive officer and co-founder, Steve Schuch, our chief financial officer, and Kenneth Hillen, our head of therapeutics. And now I'd like to turn the call over to Anne.

Thank you, Wade. We've made significant progress on both our consumer business and therapeutics efforts these last few months. The mission of 23andMe is to help people access, understand, and benefit from the human genome. We pioneered a path for people to get direct access to their genetic information and learn important information about their ancestry and health. With over 12 million customers who have signed up to join the 23andMe community, there is an incredible opportunity to introduce a new type of primary care that is based on one's genetic risks. We have heard from our customers that they often take their genetic information to their physician, but they don't know how to integrate this information into their care. We have the opportunity to further help our customers benefit from the knowledge about their genome by providing a genetics-based primary care service for our customers. I am thrilled that we got the opportunity to acquire Lemonade Health this quarter, as it opens up the door for us to enable our customers to get genetics-based primary care from healthcare providers who are trained on our report. I look forward to talking with you more about this service as we prepare to roll it out. As part of our mission to help customers benefit from the human genome, we continue to pioneer new health and ancestry reports. Recently, we received FDA clearance for a direct-to-consumer genetic test on a hereditary prostate cancer marker, further expanding our ability to provide individuals with direct access to impactful health information that can help them make important life decisions. We also launched two new health reports for our 23andMe Plus members. 23andMe Plus is our premium content subscription service that provides subscribers with new reports and features through the course of their membership, giving them even deeper insights into their health. With our database of over 12 million genotype customers and billions of health-related data points, we are uniquely positioned to provide our customers with these health insights. The new reports include a nearsightedness report and a severe acne report. Finally, we added new ancestry analysis for our customers. This new analysis includes additional insights into some customers' indigenous genetic ancestry from North America and ancestral connections to 25 African ethnolinguistic groups. On the therapeutic side, we advanced our first wholly-owned therapeutic program into a Phase I clinical trial. 23andMe 610 is our second immuno-oncology drug to enter clinical trials following our CD96 program and marks an important milestone in our goal to find new medicines for patients with serious unmet medical needs. We look forward to continuing to advance our pipeline of more than 40 programs across a range of disease areas, addressing targets that we have validated using human genetics. We were pleased to see GSK, our key collaborator in therapeutics, elect to extend the exclusive target discovery period of our collaboration for a fifth year so together we can continue to discover and validate novel drug targets using our proprietary genetic and health survey database. Under the terms of our collaboration agreement for this one-year extension, we will receive a one-time payment of $50 million. Our collaboration with GSK has been very productive, and we believe the decision by GSK to extend the collaboration further demonstrates the value of our unique database for discovering novel targets for drug development. Our mission from the beginning has been to help people access, understand, and benefit from the human genome. I'm excited about the reports we launched, our progress on therapeutics programs, and our acquisition of Lemonade Health. All of these will help our customers benefit from the human genome. And with that, I will turn the call over to Steve to review our financial results for the quarter.